INFORMATION DISCLOSURE CITATION

Docket No.: RLL-256.3CIPUS	Serial No.: 10/552,455
Applicants: SALMAN *et al.*	
Filed: 10/7/2005	Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/GS/	A1	2,490,714	12/6/1949	Searle	260	239	
	A2	3,176,019	3/30/1965	Campbell *et al.*	260	293.4	
	A3	5,001,160	3/19/1991	McPherson *et al.*	514	255	
	A4	5,164,402	11/17/1992	Brighty	514	300	
	A5	5,281,601	1/25/1994	Cross *et al.*	514	320	
	A6	5,397,800	3/14/1995	Alker *et al.*	514	413	
	A7	5,948,792	9/7/1999	Tsuchiya *et al.*	514	317	
	A8	6,130,232	10/10/2000	Mase *et al.*	514	318	
	A9	6,174,900	1/16/2001	Okada *et al.*	514	317	
	A10	6,313,312	11/6/2001	Banks *et al.*	548	452	
	A11	5,179,108	1/12/1993	George et al.	514	319	
	A12	2003/0105071	6/5/2003	Cuny et al.	514	210.2	
	A13	2003/0162780	8/28/2003	Brotherton-Pleiss et al.	514	235.5	
	A14	2003/0171362	9/11/2003	Madera et al.	514	218	
	A15	7,232,835	6/19/2007	Mehta et al.	514	323	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
/GS/	B1	CA 2155320	8/19/1993	Canada	C07D	211/68		
	B2	EP 0 325 571	7/26/1989	EPO	C07C	215/54		
	B3	EP 0 388 054	9/19/1990	EPO	C07D	207/08		
	B4	EP 0 413 455	2/20/1991	EPO	C07D	401/04		
	B5	EP 0 613 232	8/31/1994	EPO	H02M	3/335		
	B6	EP 0 801 067	10/15/1997	EPO	C07D	453/02		

EXAMINER	/Golam Shameem/	DATE CONSIDERED	06/02/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-256.3CIPUS	Serial No.: 10/552,455
	Applicants: SALMAN *et al.*	
	Filed: 10/7/2005	Group:

/GS/	B7	EP 0 823 423	2/11/1998	EPO	C07D	211/46	
	B8	EP 0 863 141	9/9/1998	EPO	C07D	401/06	
	B9	GB 940,540	10/30/1963	UK	C07C		
	B10	JP 135958/1994	5/17/1994	Japan	C07D	333/16	
	B11	JP 92921/1994	4/5/1994	Japan	C07C	237/20	
	B12	WO 91/09013	6/27/1991	PCT	C07D	207/08	
	B13	WO 93/16018	8/19/1993	PCT	C05F	17/02	
	B14	WO 93/16048	8/19/1993	PCT	C07D	211/26	
	B15	WO 96/33973	10/31/1996	PCT	C07D	211/46	
	B16	WO 97/45414	12/4/1997	PCT	C07D	211/58	
	B17	WO 98/05641	2/12/1998	PCT	C07D	211/46	
	B18	WO 98/29402	7/9/1998	PCT	C07D	311/20	
	B19	WO 98/53814	12/3/1998	PCT	A61K	31/395	
	B20	WO 01/42212	6/14/2001	PCT	C07D	211/48	
	B21	WO 01/42213	6/14/2001	PCT	C07D	211/58	
	B22	WO 01/90081	11/29/2001	PCT	C07D	241/08	
	B23	WO 02/00652	1/3/2002	PCT	C07D	453/02	
	B24	WO 02/04402	1/17/2002	PCT	C07C	219/10	
	B25	WO 02/51841	7/4/2002	PCT	C07D	453/02	
	B26	WO 02/06241	1/24/2002	PCT	C07D	223/16	
	B27	WO 02/53564	7/11/2002	PCT	C07D	453/02	
	B28	WO 04/004629	1/15/2004	PCT	A61K		
	B29	WO 04/005252	1/15/2004	PCT	C07D	209/52	
	B30	WO 04/014363	2/19/2004	PCT	A61K	31/40	
	B31	WO 04/014853	2/19/2004	PCT	C07D	209/02	
	B32	WO 04/018422	3/4/2004	PCT	C07D	209/52	
	B33	WO 04/052857	6/24/2004	PCT	C07D	209/52	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-256.3CIPUS	Serial No.: 10/552,455
	Applicants: SALMAN *et al.*	
	Filed: 10/7/2005	Group:

/GS/	B34	WO 04/056767	7/8/2004	PCT	C07D	207/14		
	B35	WO 04/056810	7/8/2004	PCT	C07D	405/12		
	B36	WO 04/056811	7/8/2004	PCT	C07D	405/12		
	B37	WO 04/089900	10/21/2004	PCT	C07D	209/52		
	B38	WO 99/43657	9/2/1999	PCT	C07D	211/26		
	B39	WO 01/47893	7/5/2001	PCT	C07D	221/24		
	B40	WO 01/090082	11/29/2001	PCT	C07D	241/08		
	B41	WO 03/033495	4/24/2003	PCT	C07D	453/02		
	B42	WO 03/048124	6/12/2003	PCT	C07D	211/26		
	B43	WO 03/048125	6/12/2003	PCT	C07D	211/58		
	B44	WO 04/067510	8/12/2004	PCT	C07D	209/52		
	B45	WO 04/069835	8/19/2004	PCT	C07D	471/08		
	B46	WO 04/089363	10/21/2004	PCT	A61K	31/403		
	B47	WO 04/089898	10/21/2004	PCT	C07D	209/52		
	B48	WO 04/089899	10/21/2004	PCT	C07D	209/52		
	B49	WO 2005/092341	10/6/2005	PCT	A61K	31/496		
	B50	WO 2005/003587	1/12/2006	PCT	A61K	9/16		
	B51	WO 2006/035282	4/6/2006	PCT	A61K	31/439		
	B52	WO 2006/064304	6/22/2006	PCT	C07D	209/52		

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

/GS/	C1	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", *Annual Review of Pharmacology and Toxicology*, 41:691-721 (2001)
	C2	Cheng and Prusoff, "Relationship between the inhibition constant (K_1) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction", *Biochemical Pharmacology*, 22:3099-3108 (1973)
	C3	Birdsall et al., "Muscarinic receptors: it's a knockout", *Trends in Pharmacological Sciences*, 22(5):215-219 (2001)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-256.3CIPUS	Serial No.: 10/552,455
	Applicants: SALMAN *et al.*	
	Filed: 10/7/2005	Group:

/GS/	C4	Brighty et al., "Synthesis of (1α,5α,6α)-6-Amino-3-azabicyclo[3.1.0]hexane, a Novel Achiral Diamine", *Synlett,* 1097-1099 (1996)
	C5	Braish et al., "Construction of the (1α,5α,6α)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", *Synlett,* 1100-1102 (1996)
	C6	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", *Urology,* 55(Suppl. 5A):33-46 (2000)
	C7	Eglen et al., "Muscarinic receptor ligands and their theraputic potential", *Current Opinion in Chemical Biology,* 3:426-432 (1999)
	C8	Eglen et al., "Theraputic opportunities from muscarinic receptor research", *Trends in Pharmacological Sciences,* 22(8):409-414 (2001)
	C9	Felder et al., "Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System", *Journal of Medicinal Chemistry,* 43(23):4333-4353 (2000)
	C10	Grover et al., "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis", *Journal of Organic Chemistry,* 65:6283-6287 (2000)
	C11	Shacklett and Smith, "The Preparation of Substituted Benzilic Acids", *Journal of the American Chemical Society ,* 75:2654-2657 (1953)
	C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M_3 Antagonist Discriminating against the Other Receptor Subtypes", *Journal of Medicinal Chemistry,* 45:984-987 (2002)
	C13	Nkpa and Chedekel, "Mechanistic Studies on the Addition of Cysteine to 3,4-Dihydroxyphenylalanine", *Journal of Organic Chemistry,* 46:213-215 (1981)
	C14	Kadin and Cannon, "Esters of *N*-Methyl-3-hydroxypiperidine Having Psychotomimetic Activity. II", *Journal of Organic Chemistry,* 27:240-245 (1962)
	C15	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", *Molecules,* 6:142-193 (2001)
	C16	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", *Life Sciences,* 64(25):2351-2358 (1999)
	C17	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", *Nature,* 323(2):411-416 (1986)
	C18	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", *Science,* 237:527-531 (1987)
	C19	Steers, "The future direction of neuro-urology drug research", *Current Opinion in CPNS Investigational Drugs,* 2(3):268-282
	C20	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: *Adult and Pediatric Urology,* ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-256.3CIPUS	Serial No.: 10/552,455
	Applicants: SALMAN *et al.*	
	Filed: 10/7/2005	Group:

/GS/	C21	Weinstock et al., "A General, One-Step Synthesis of α-keto Esters", *Synthetic Communications,* 11(12):943-946 (1981)
	C22	Vogel's textbook, "Practical Organic Chemistry" 1046-1047 (5th Ed.)
	C23	"Design of prodrugs", ed. H. Bundgaard, Elsevier (1985)
	C24	Kaiser et al, "Synthesis and Antimuscarinic Activity of Some 1-Cycloalkyl-1-hydroxy-1-phenyl-3-(4-substituted piperazinyl)-2-propanones and Related Compounds", *Journal of Medicinal Chemistry,* 36(5):610-616 (1993)
	C25	Carter et al, "Analogues of Oxybutynin. Synthesis and Antimuscarinic and Bladder Activity of Some Substituted 7-Amino-1-hydroxy-5-heptyn-2-ones and Related Compounds", *Journal of Medicinal Chemistry,* 34(10):3065-3074 (1991)
	C26	Morissette et al, "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids", *Advanced Drug Delivery Reviews,* 56:275-300 (2004)

EXAMINER /Golam Shameem/	DATE CONSIDERED 06/02/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /GS/